Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma.
Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma.
复制标题
DOI：
10.1186/s40661-018-0063-3
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
Maluf FC
中科院分区：
文献类型：
--
作者：
Zibetti Dal Molin G;Abrahão CM;Coleman RL;Maluf FC
卵巢癌肉瘤是一种罕见的恶性肿瘤，即使在早期阶段，癌症相关死亡率也很高。由于该疾病通常被排除在前瞻性临床试验之外，因此很难制定全身性治疗指南。尽管有很大的组织学差异，但卵巢癌肉瘤通常作为高级别上皮性卵巢癌进行治疗。由于卵巢癌肉瘤的罕见和预后差，抢救治疗及其疗效的报道很少。一名接受大量治疗的卵巢癌肉瘤患者对免疫检查点抑制剂派姆单抗表现出客观反应。在该患者中，派姆单抗似乎在多灶性转移部位提供肿瘤控制。Pembrolizumab应该在卵巢癌肉瘤治疗的前瞻性试验中进行评估，需要进一步的工作来确定最有可能对这种类型的干预有反应的患者。
Ovarian carcinosarcoma is a rare malignancy associated with a high rate of cancer-related mortality even at early stages. Guidelines for systemic treatment have been difficult to establish because the disease is commonly excluded from prospective clinical trials. Ovarian carcinosarcoma is usually managed as high-grade epithelial ovarian cancer despite major histologic differences. Owing to the rarity and poor prognosis of ovarian carcinosarcoma, salvage treatments and their efficacy have been poorly described. A patient heavily treated for ovarian carcinosarcoma showed an objective response to an immune checkpoint inhibitor, pembrolizumab. Pembrolizumab in this patient appeared to provide tumor control in multifocal metastatic sites. Pembrolizumab should be evaluated in prospective trials for the treatment of ovarian carcinosarcoma and further work is needed to identify patients most likely to respond to this type of intervention.